FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      
           
This page is updated frequently with new Cholesterol-related patent applications. Subscribe to the Cholesterol RSS feed to automatically get the update: related Cholesterol RSS feeds. RSS updates for this page: Cholesterol RSS RSS


Fat binder obtained from biomass resulting from beer production

S.a. Damm

Fat binder obtained from biomass resulting from beer production

Fat binder obtained from biomass resulting from beer production

Tlc Biopharmaceuticals

Methods of treating arthritis

Date/App# patent app List of recent Cholesterol-related patents
06/25/15
20150176050
 Dry chemistry, lateral flow-reconstituted chromatographic enzyme-driven assays patent thumbnailDry chemistry, lateral flow-reconstituted chromatographic enzyme-driven assays
Specific assays for glucose-6-phosphate dehydrogenase (“g-6pd”), total serum cholesterol, β-lactamase activity and peroxidase activity are disclosed.. .
06/25/15
20150175956
 Media for cell culture patent thumbnailMedia for cell culture
The present disclosure relates, in general, to a media, e.g., a serum replacement, media supplement, complete media or cryopreservation media, comprising a base physiological buffer and liposomes comprising cholesterol, phosphatidylcholine and fatty acids. It is contemplated that media provides advantages to improve cell growth in culture compared to cells cultured not using the serum replacement described herein..
Essential Pharmaceuticals, Llc
06/25/15
20150174152
 Fat binder obtained from biomass resulting from beer production patent thumbnailFat binder obtained from biomass resulting from beer production
The present invention provides a polysaccharide rich composition comprising beta-glucan, chitin and chitosan, extracted from the cell wall of saccharomyces cerevisiae from the by-product biomass resulting from a brewing process, the process for obtaining it and the uses thereof. The composition exerts, among other biofunctionalities, a selective fat binding effect so it is useful in the prevention and/or treatment of a disorder such as overweight, obesity, hypercholesterolemia, hypertriglyceridemia, blood hypertension and cardiovascular disorders.
S.a. Damm
06/25/15
20150174069
 Methods of treating arthritis patent thumbnailMethods of treating arthritis
Disclosed herein are methods of treating arthritis, comprising administering a sustained release composition comprising liposomes comprising one or more phospholipids, cholesterol, and a therapeutic agent. The sustained release composition can be administered intraarticularly..
Tlc Biopharmaceuticals, Inc.
06/25/15
20150173389
 Method for producing high quality animal oil with low cholesterol levels patent thumbnailMethod for producing high quality animal oil with low cholesterol levels
The invention provides a method for producing high-quality lard or beef tallow with low cholesterol content. The method of the invention uses enzyme hydrolysis, centrifugation separation and homogenization-assisted embedding technique to obtain high-quality lard or beef tallow with low cholesterol levels.
Jiangnan University
06/18/15
20150167005
 Methods for treating hypercholesterolemia patent thumbnailMethods for treating hypercholesterolemia
Disclosed herein are antisense compounds and methods for decreasing ldl-c in an individual having elevated ldl-c. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis.
Isis Pharmaceuticals, Inc.
06/18/15
20150166975
 Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides patent thumbnailCell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
C) a carrier.. .
06/18/15
20150166672
 Precision medicine by targeting rare human pcsk9 variants for cholesterol treatment patent thumbnailPrecision medicine by targeting rare human pcsk9 variants for cholesterol treatment
The invention relates to human targets of interest (toi), anti-toi ligands, kits compositions and method.. .
Kymab Limited
06/18/15
20150166566
 Thienopyridone derivatives useful as activators of ampk patent thumbnailThienopyridone derivatives useful as activators of ampk
Activators of ampk and therapeutic uses thereof the invention relates to compounds that are direct activators of ampk (amp-activated protein kinase) and their use in the treatment of disorders regulated by activation of ampk. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (nafld), non alcoholic steato-hepatitis (nash), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies..
Poxel
06/18/15
20150164969
 Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in treating atherosclerosis and cardiovascular disease patent thumbnailAnti-obesity and anti-dyslipidemic effects of oil palm phenolics in treating atherosclerosis and cardiovascular disease
A composition comprising extracts containing oil palm phenolics in an amount effective for use in a method of reducing cholesterol biosynthesis and thus preventing obesity. The composition up regulates fatty acid beta oxidation and down regulates cholesterol biosynthesis in livers.
Malaysian Palm Oil Board
06/18/15
20150164893

Pharmaceutical formulations for carrier-mediated transport statins and uses thereof


The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug.
Circ Pharma Research And Development Limited
06/18/15
20150164787

Process for forming microbubbles with high oxygen content and uses thereof


Formulations containing a carrier and microbubbles encapsulating oxygen gas, and methods for making and using the formulations are described herein. The formulations are manufactured by a process which includes high shear homogenization.
Children's Medical Center Corporation
06/11/15
20150159115

Purification of dpa enriched oil


The present invention provides chromatographic means for separating from a starting lipid mixture a mixture that is enriched in docosapentaenoic acid relative to the starting lipid mixture. The invention also provides pharmaceutical formulations and dietary supplements including this enriched lipid formulation, and methods of supplementing docosapentaenoic acid in a subject by administering to the subject the pharmaceutical formulation or the dietary supplement.
Omega Protein Corporation
06/11/15
20150157572

Proliposomal testosterone formulations


Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions.
Tesorx Pharma, Llc
06/11/15
20150157570

Tailored liposomes for the treatment of bacterial infections


The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells.
Universitaet Bern
06/04/15
20150153342

Serological methods and diagnostic tests for syphilis antibodies


A method of detecting antibodies to syphilis antigens includes providing a syphilis detection kit having a screening solid-phase platform with a screening portion coated with non-treponemal syphilis antigens. The screening portion is fabricated by initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin to form an antigen solution, permitting the antigen solution to evaporate at the screening portion and at least partially coating the screening portion with an antigen coating, and stabilizing the antigen coating into a syphilis antigen complex by overcoating the antigen coating with an overcoat solution comprising an inert protein..
Awareness Technology Inc.
06/04/15
20150152102

Piperidinylpyrazolopyridine derivative


A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group.. .
Daiichi Sankyo Company, Limited
05/28/15
20150148360

3,5,n-trihydroxy-alkanamide and derivatives: making same and use thereof


The present invention provides novel compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are inhibitors of histone deacetylases (hdacs) and 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase (hmgr).
National Taiwan University
05/28/15
20150147320

Ophthalmic drug delivery system containing phospholipid and cholesterol


An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.. .
Tlc Biopharmaceuticals, Inc.
05/28/15
20150146205

Measurement of serum lipoproteins


Although a more accurate estimate of a person's risk of cardiovascular disease can be made on the basis of the number of lipoprotein particles per unit volume in the person's blood, current methods all rely on measuring the mass of lipoprotein cholesterol per unit volume. It has been discovered that a rapid and accurate lipoprotein particle count can be obtained by photometry.
Atherotech,inc.
05/21/15
20150141371

Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia


A composition for use in a human by oral administration to reduce or control cardiometabolic risk factors associated with metabolic syndrome or hypercholesterolemia, or reduce risk of developing metabolic syndrome or hypercholesterolemia. The composition includes a combination of arabinogalactan and dihydroquercetin (taxifolin), where the arabinogalactan is present in the combination as a fiber matrix in an amount higher than 70% as determined by weight on dry matter basis, and the dihydroquercetin is present in the fiber matrix..
Flavitpure, Inc.
05/21/15
20150141355

Salacia compositions, methods of treatment by their administration, and methods of their preparation


A salacia composition described herein significantly reduces appetite, activates hormone sensitive lipase, and manages a healthy lipid profile through inhibition of hmg-coa reductase enzyme. Salacia compositions described herein include of at least 12% of polyphenols, 2% of mangiferin and 1% of 25,26-oxidofriedelane-1,3-dione by weight of the composition in the form of extract.
Omniactive Health Technologies (canada) Limited
05/21/15
20150140650

Systems and methods for cryopreservation of cells


An auto-nucleating device includes a tube containing a crystalline cholesterol matrix. The ends of the tube are closed by a membrane that is impermeable to the cholesterol but permeable to liquids contained in a cryopreservation vessel.
Cook General Biotechnology Llc
05/21/15
20150140142

Medicinal composition of extract of seed of emblica officinalis and preparing the same


A composition having an extract of seed of emblica officinalis. Methods of preparing extract of seed of emblica officinalis.
05/21/15
20150140004

Hydroxycholesterol immunoassay


Provided is a derivative of 22-hydroxycholesterol, 24s-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative.
Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.
05/21/15
20150139987

Treatment of homozygous familial hypercholesterolemia


Treatment of homozygous familial hypercholesterolemia by administration of (r)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an mtp inhibitor, an apob-100 synthesis inhibitor, or a pcsk9 inhibitor.. .
Cymabay Therapeutics, Inc.
05/14/15
20150133554

Purification of dpa enriched oil


The present invention provides chromatographic means for separating from a starting lipid mixture a mixture that is enriched in docosapentaenoic acid relative to the starting lipid mixture. The invention also provides pharmaceutical formulations and dietary supplements including this enriched lipid formulation, and methods of supplementing docosapentaenoic acid in a subject by administering to the subject the pharmaceutical formulation or the dietary supplement.
05/14/15
20150133519

Novel diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids of formula a that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
05/14/15
20150133508

Use of quaternary pyridinium salts as vasoprotective agents


Wherein r is nh2, ch3, or n(h)ch2oh group, and x is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin pgi2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low hdl level.. .
05/14/15
20150133420

Broad antiviral therapy with membrane modifying oxysterols


This invention relates, e.g., to a method for inhibiting the growth and/or proliferation and/or infectivity of a virus in a cell, such as a mammalian cell (e.g. For inhibiting entry of the virus into the cell), comprising administering, or causing to be administered, to the cell, 25-hydroxycholesterol (25hc) in an amount sufficient to inhibit the growth and/or proliferation and/or infectivity of the virus in the cell.
05/14/15
20150132834

Method for removal of triglycerides in lipoproteins other than low-density lipoproteins


Disclosed is a method for selectively eliminating triglycerides in lipoproteins other than low density lipoprotein, which method allows one to provide a method for directly and differentially quantifying ldl-tg in a sample with excellent simplicity, specificity and accuracy using an automated analyzer or the like without performing a laborious operation of pretreatment such as centrifugation or electrophoresis. The method for eliminating triglycerides in lipoproteins other than low density lipoproteins includes allowing lipoprotein lipase, cholesterol esterase, glycerol kinase and glycerol-3-phosphate oxidase to act on a sample in the presence of a surfactant that acts on lipoproteins other than low density lipoprotein and/or a surfactant having ldl-protecting action, and eliminating hydrogen peroxide produced thereby..
05/14/15
20150132431

Cholesterol-reducing diet


A method of treating macular degeneration comprising a specific dietary regimen. The regimen includes lipids as approximately 70% or more of daily caloric content, protein up to 10%-15% of daily caloric content; and carbohydrates up to 25% or less of daily caloric content, primarily in the form of non-starchy, low-glycemic fresh fruit and vegetables, and nuts, average daily cholesterol intake of less than 10 mg, and 30 grams of cocoa solids..
05/07/15
20150125568

Healthy composition for lowering cholesterol for use in foods, beverages, health supplements and medical foods


Disclosed is a composition consisting of beta-glucan (1,3), (1,4) β-d glucan), plant sterols and a hydrocolloid. A natural way to help lower blood serum cholesterol levels to a consumer and or patient with the effective amount of disclosed composition.
04/30/15
20150119458

4-((substituted phenyl) difluoromethyl) phenoxy carboxylic acid derivative, and preparation method and uses thereof


The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula i, which is defined in the specification.
Zhejiang Hisun Pharmaceutical Co., Ltd.
04/30/15
20150119414

Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels


A composition and a method of treatment utilizing a combination of statins (or hmg-coa reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme hmg-coa reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.. .
Pivotal Therapeutics Inc.
04/30/15
20150119406

Tricyclic pyrone compounds reduce amyloid beta aggregates


Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to alzheimer's disease transgenic models resulted in substantially reduced soluble and insoluble aβ species in the brain without affecting general behavior and motor coordination.
The Regents Of The University Of California
04/30/15
20150119388

Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges


An ester of aroh according to the formula r—x—co—oar, wherein aroh is a pharmaceutically active compound selected from the group consisting of sn-38, pi-103, etoposide and fenretinide, wherein a) r is a residue of cholesterol, sitosterol, sn-38, pi-103, etoposide or fenretinide and x is o—co-l, wherein l is either a direct bond or a linking group including a branched or unbranched hydrocarbyl moiety that may optionally include in-chain or pendant heteroatom substituents and/or cyclic moieties; b) r—x—co-0 is an all-trans retinoate radical or the 9-cis or 13-cis isomer thereof; or c) r—x— is a branched or unbranched, saturated or unsaturated hydrocarbyl moiety comprising at least 5 carbon atoms and optionally including at least one in-chain or pendant heteroatom substituent and/or cyclic moiety. A dispersion of nanoparticles in an aqueous medium includes nanoparticles including an ester of aroh according to the formula r—x—co—oar wherein aroh is a pharmaceutically active compound in which ar is a substituted or unsubstituted aryl or heteroaryl radical, and wherein r is as defined above or r—x—co-0 is as defined above.
The Children's Hospital Philadelphia
04/30/15
20150119368

Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events


A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. Azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught..
Pivotal Therapeutics Inc.
04/23/15
20150111948

Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor


The present invention relates to a novel, rnai-inducing nucleic acid molecule having cell penetrating ability and the use thereof, and more particularly, to a novel, rnai-inducing double-stranded nucleic acid molecule, which has a replacement of the phosphate backbone of at least one nucleotide with phosphorothioate or phosphorodithioate, and has a lipophilic compound conjugated thereto, and thus has high target gene-silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle, and to a method of silencing a target gene using the nucleic acid molecule. The nucleic acid structure according to the present invention has both cholesterol modification and phosphorothioate modification introduced therein, and thus has high gene silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle.
Bmt, Inc.
04/23/15
20150111866

Cyclic amine substituted heterocyclic cetp inhibitors


Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and may be useful for raising hdl-cholesterol and reducing ldl-cholesterol in human patients and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.
04/23/15
20150110859

Mrna therapy for argininosuccinate synthetase deficiency


The present invention provides, among other things, methods of treating argininosuccinate synthetase deficiency (asd), including administering to a subject in need of treatment a composition comprising an mrna encoding argininosuccinate synthetase (ass1) at an effective dose and an administration interval such that at least one symptom or feature of asd is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.
04/23/15
20150110858

Mrna therapy for phenylketonuria


The present invention provides, among other things, methods of treating phenylketonuria (pku), including administering to a subject in need of treatment a composition comprising an mrna encoding phenylalanine hydroxylase (pah) at an effective dose and an administration interval such that at least one symptom or feature of pku is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.
04/16/15
20150104847

Method for stabilizing cholesterol oxidase


The present invention provides a method for stabilizing a cholesterol oxidase, a method for preserving a cholesterol oxidase, and a stabilized composition of cholesterol oxidase. A method for stabilizing a cholesterol oxidase and a method for preserving a cholesterol oxidase which comprises allowing the cholesterol oxidase to coexist with an α-keto acid in an aqueous medium, and, a stabilized composition of cholesterol oxidase which comprises the cholesterol oxidase being allowed to coexist with an α-keto acid in an aqueous medium.
Kyowa Medex Co., Ltd.
04/16/15
20150104817

Hydroxycholesterol immunoassay


Provided is a derivative of 22-hydroxycholesterol, 24s-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative.
Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.
04/16/15
20150104532

Composition to enhance hdl cholesterol and to decrease intima-media thickening in animals and humans and a its preparation


A method of producing a product to correct hypercholesterolemia including pulping fruits of emblica officinalis with demineralized water to create a slurry. The slurry is treated with pectinase.
Arjuna Natural Extracts, Ltd.
04/09/15
20150099787

Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutially acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College
04/09/15
20150099021

Medicinal composition of extract of seed of emblica officinalis and preparing the same


A composition having an extract of seed of emblica officinalis. Methods of preparing extract of seed of emblica officinalis.
04/02/15
20150093781

Microorganism for expressing a human membrane protein


The invention relates to an isolated, genetically modified, living non-mammal organism, having increased hmg-coa-reductase activity compared to the wild type, and having reduced c24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type.
Organobalance Gmbh
04/02/15
20150093459

Bioactive complex compositions and methods of use thereof


A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides.
Texas A&m University System
03/26/15
20150087819

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.
03/26/15
20150087649

Treating disorders associated with aberrant adrenocortical cell behavior


Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (acc) and/or cushing's syndrome. Such methods involve administration of an agent which exhibits an ic50 value against huacat1 of less than 10 μm, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and/or preferential binding to by low-density lipoprotein (ldl)..
Atterocor, Inc.
03/19/15
20150080477

Methods and compositions for treating arteriosclerotic vascular diseases


The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits pdgf-stimulated smooth muscle cell proliferation or migration.
Golden Biotechnology Corporation
03/19/15
20150080471

Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels


Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (tg), total cholesterol (tc) and low density lipoprotein (ldl) in human subjects.. .
03/19/15
20150080345

Compositions and methods for the treatment of metabolic syndrome


The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
03/19/15
20150079616

Method for quantifying subfraction of cholesterol (-c) in high-density lipoprotein (hdl)


Provided is a method for separately or simultaneously quantifying whole hdl-c and cholesterol in hdl subfractions: apoe-containing hdl-c and apoe-deficient hdl-c. A method for enzymatically and separately quantifying cholesterol in the apoe-deficient hdl comprising: adding a surfactant composed of a polyoxyethylene benzyl phenyl ether derivative to a test sample in a final concentration of 0.05 to 0.10%, reacting the test sample with cholesterol esterase and cholesterol oxidase, and quantifying hydrogen peroxide generated.
National University Corporation Hokkaido University
03/19/15
20150079226

Vegetable oil composition containing palm mid-fraction fat and reducing plasma cholesterol


A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (pmf) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° c.
Brandeis University
03/19/15
20150079225

Nutritional composition


A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.. .
Hero Ag
03/19/15
20150079189

Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation


In one embodiment, the present application discloses synthetic ldl nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin e, and methods for preparing the synthetic nanoparticles. The disclosed synthetic ldl nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing ldl receptors after intra venous injection..
Arbor Therapeutics, Llc
03/19/15
20150079161

Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases


The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia or neurons, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of acyl-coa:cholesterol acyltransferase 1, but not acyl-coa:cholesterol acyltransferase 2.. .
Trustees Of Dartmouth College


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.3588

3749

2 - 1 - 75